JAK Inhibitors May Weaken Immune Barriers, Facilitating Viral Spread
Researchers at the Norwegian University of Science and Technology (NTNU) have discovered that Janus kinase (JAK) inhibitors, a class of anti-inflammatory drugs widely prescribed for conditions like rheumatoid arthritis, may inadvertently facilitate the spread of dangerous viruses. The study, published in NAR Molecular Medicine, indicates that these medications suppress specific immune signaling pathways and gene activities that normally protect cells from viral infection. This suppression can leave patients more vulnerable to pathogens such as influenza, SARS-CoV-2, adenovirus, and Rift Valley fever virus. While the drugs are effective for managing inflammation, the findings suggest a significant trade-off: they may compromise innate antiviral defenses, potentially allowing viruses to establish infections and propagate more easily within the body. The researchers recommend caution when prescribing these medications during periods of high viral transmission or for patients with active or latent infections.
Key points
- NTNU scientists found that JAK inhibitors suppress immune signaling pathways crucial for antiviral defense.
- The drugs reduce the activity of genes that normally help the body fight off viral infections.
- Specific viruses affected include influenza A, SARS-CoV-2, adenovirus, and Rift Valley fever virus.
- The study utilized organoid technology and gene expression analysis to test effects on lung, eye, and brain cells.
- Researchers advise healthcare providers to weigh the risks of JAK inhibitors during viral outbreaks or pandemics.
Background
This finding adds to ongoing discussions about the side effects of immunomodulating therapies. Previous coverage noted that JAK inhibitors are a standard treatment for chronic inflammatory diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. While earlier reports focused on their efficacy in reducing inflammation, this new research highlights a potential downside regarding infectious disease susceptibility. The current rise in respiratory viruses and measles cases, as reported in recent months, underscores the importance of understanding how common medications might interact with viral outbreaks.
Why it matters
The discovery highlights a critical safety consideration for millions of patients taking JAK inhibitors for autoimmune conditions. If these drugs weaken the body's first line of defense against viruses, patients may face higher risks of severe infection during flu season or pandemics. This could influence prescribing guidelines, prompting doctors to monitor patients more closely for viral symptoms or adjust treatments during high-transmission periods. Understanding this mechanism is vital for balancing the benefits of anti-inflammatory treatment against the risks of increased viral susceptibility.
What to watch
The researchers are calling for further studies to determine the optimal use of JAK inhibitors, particularly during viral outbreaks. They suggest that while the immune-suppressing effects pose risks for patients, they could be leveraged in controlled laboratory settings to develop vaccines or test antiviral medications. Future research will likely focus on identifying specific patient populations at highest risk and developing guidelines for safe prescribing during periods of increased viral circulation.
Want the full story? Read the original reporting
Read on Science Daily